Higher levels of moderate-to-vigorous physical activity were linked to a lower risk of disabling dementia in Japanese men. (JAMA network open)
At current expected prices, neither aducanumab (Aduhelm) nor donanemab, an investigational anti-amyloid drug, would be cost-effective for early-onset Alzheimer’s disease in the United States, according to one analysis. (JAMA Neurology)
Antidopaminergic antiemetics, widely used for nausea and vomiting due to migraine, chemotherapy, radiotherapy or surgery, increased the risk of ischemic stroke. (The BMJ)
A small study showed that signs of frozen gait were more noticeable when people with Parkinson’s turned around rather than walking backwards or forwards. (Gait and posture)
Blood levels of glial fibrillary acidic protein (GFAP) predicted risk of dementia in Mexican-American adults. (Alzheimer’s and dementia: diagnosis, assessment and monitoring of the disease)
A faster growth rate of the amygdala between 6 and 12 months was linked to greater social deficits when children were diagnosed with autism spectrum disorder at age 2. (American Journal of Psychiatry)
An increased risk of autism has been observed after pediatric ischemic stroke, particularly in children with comorbid epilepsy. (Neurology)
Epilepsy was not linked to increased susceptibility to SARS-CoV-2 infection, but people with epilepsy were at high risk for serious complications from COVID-19. (Neurology)
The FDA has expanded the indication for fenfluramine (Fintepla) to treat seizures associated with Lennox-Gastaut syndrome in patients 2 years of age and older, drugmaker UCB announced.
Biogen and Ionis Pharmaceuticals have stopped trials of BIIB078, an investigational antisense oligonucleotide for C9orf72-associated ALS, after phase I data failed to show clinical benefit.